Results 111 to 120 of about 3,265,867 (293)

Endocytosis‐independent cytosolic entry of messenger RNA via fluorous bilayer zippering attenuating Toll‐like receptor signaling and enables ischemic tissue salvage

Smart Molecules, EarlyView.
The present study establishes a paradigm shift in synthetic mRNA delivery through the convergence of three orthogonal chemistries—perfluoro‐acylation, bio‐orthogonal click cross‐linking, and disulfide reduction—within a single, modular polymer architecture. Abstract A fundamental constraint of conventional messenger RNA (mRNA) delivery systems is their
Yue Wang, Haitao Xie, Guoqing Xiang, Yanhua Li, Changgui Tong, Hongyan Cui, Qixian Chen, Haidong Li, Yan Zhao   +8 more
wiley   +1 more source

Cilostazol-based dual antiplatelet treatment in ischemic stroke or transient ischemic attack patients with asymptomatic carotid artery disease: a propensity score matching analysis

Frontiers in Neurology
BackgroundThe optimal treatment for asymptomatic atherosclerotic carotid artery disease remains controversial. Data on the efficacy of antiplatelet agents and stroke outcomes are limited.
Thon Thiraworawong, Chadawan Pathonsmith
doaj   +1 more source

Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

, 2014
Roberto Aiolfi, Giovanni Sitia Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy Abstract: Platelets, the chief effectors of vascular homeostasis, have been identified as important players ...
Sitia G, Aiolfi R
core  

Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Summary of a multicentre TriNetX study evaluating outcomes after percutaneous coronary intervention (PCI) in patients with cirrhosis. Cirrhosis was associated with higher 1‐year gastrointestinal bleeding and mortality, especially with decompensated disease.
Dhir Gala, Sameer Rao, Manas Gunani, Kajol Shah, Anand V. Kulkarni, Karn Wijarnpreecha, Daniel Q. Huang, Pojsakorn Danpanichkul, Ahmed Al‐Khazraji, Kaveh Hajifathalian, Vivek Lingiah, Paul Gaglio, Nikki Duong, Christine Gerula   +13 more
wiley   +1 more source

Perioperative antiplatelet therapy.

, 2010
Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction,
Spahn, D.R., Chassot, P.G., Delabays, A., Marcucci, C.   +3 more
core   +3 more sources

Optimal Dual Antiplatelet Therapy Duration For Carotid Artery Stenting On the Basis of Angioscopic Findings

Stroke: Vascular and Interventional Neurology
Background Dual antiplatelet therapy plays a crucial role in preventing thrombosis in the perioperative period of carotid artery stenting (CAS); however, it has been associated with a risk of hemorrhagic complications. A standard regimen for the duration
Kenji Fukutome, Shuta Aketa, Junji Fukumori, Takaaki Mitsui, Yuki Shiraishi, Hiromichi Hayami, Yuma Hamanaka, Yasutaka Murakami, Ryuta Matsuoka, Mikio Shiba, Rinsei Tei, Yasushi Shin, Hideaki Kanki, Yoshiharu Higuchi, Atsushi Hirayama, Yasushi Motoyama   +15 more
doaj   +1 more source

Effectiveness of Two-Year Versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis After Drug-Eluting Stent Implantation [PDF]

Journal of Tehran University Heart Center, 2012
Background: Impact of 12 months’ versus 24 months’ use of dual antiplatelet therapy on the prevalence of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) with the drug-eluting stent (DES) is not clear.
Ali Reza Amirzadegan, Hasan Aghajani, Ali Mohammad Haji Zeinali, Ebrahim Nematipour, Younes Nozari, Mohammad Alidoosti, Seyed Ebrahim Kassaian, Seyed Kianoosh Hosseini, Hamid Reza Poorhosseini, Mojtaba Salarifar, Masoumeh Lotfi Tokaldany, Tahereh Davarpasand   +11 more
doaj  

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Recurrent Stroke Prevention Strategies in Patients Receiving Acute Stroke Reperfusion Therapies (CoPrime Study Survey)

Cerebrovascular Diseases Extra
Introduction: Patients who have undergone reperfusion treatments, like all ischemic stroke patients, are at risk of recurrent ischemic strokes in the first 90 days.
Rezan Ashayeri Ahmadabad, Mohammed Almekhlafi, PN Sylaja, Aviraj Deshmukh, Jesse Dawson, Aleksandra Pikula, Muhammad Shazam Hussain, Yiran Zhang, Negar Asdaghi, Sung-II Sohn, Mohammad Wasay, Ashfaq Shuaib, Brian Buck, Mahesh Pundlik Kate   +13 more
doaj   +1 more source